Since Brinsupri’s approval, Insmed has been at the forefront of non-cystic fibrosis bronchiectasis (NCFB), supporting programs to increase disease awareness and to improve clinical outcomes in this ...

The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.

J&J’s Rybrevant and cancer vaccines are showing benefit, with detailed data presented at ASCO. Credit: Hindi Studio / Shutterstock.com During the American Society of Clinical Oncology (ASCO) meeting ...

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

Several companies have presented compelling data from multiple myeloma studies at the 2026 American Society of Clinical Oncology (ASCO) meeting. Data was announced by both Bristol Myers Squibb (BMS) ...

Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide, worldwide ...

AstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-naïve, high-risk NMIBC.

AbbVie’s Elahere (mirvetuximab soravtansine-gynx), a first-in-class folate receptor alpha (FRα)-directed antibody-drug conjugate (ADC), continues to gain momentum in ovarian cancer and is currently ...

The US Food and Drug Administration (FDA) has approved boxed warning of higher blood clots and death risk with 10mg twice-daily dose of Pfizer’s Xeljanz (tofacitinib) drug in ulcerative colitis ...

PCI Pharma’s $100m drug substance manufacturing facility expansion is scheduled to commence operations in 2028. PCI Pharma’s drug substance manufacturing facility expansion in San Diego is expected to ...

The portfolio consists of eight drug candidates originating from Innovent Biologics and four discovery programmes proposed by Pfizer. Credit: Jonathan Weiss / Shutterstock.com. Pfizer and Innovent ...

The LEAP2MONO Phase III trial evaluated venglustat’s efficacy and safety in adults and children aged 12 and above. Credit: Pickadook / Shutterstock.com. Sanofi has received a priority review from the ...